Polymorphism Pro64His within galectin-3 has functional consequences at proteome level in thyroid cells
暂无分享,去创建一个
F. Gemignani | M. Mazzoni | M. Cipollini | G. de Marco | A. Corrado | E. Ferrarini | Roberto Silvestri | Lorenzo Zallocco | L. Giusti | I. Dell'Anno | Benedetta Ricci | Maurizio Ronci | Romina Aceto | Chiara De Simone | Daniela Beghelli | Antonio Lucacchini | Stefano Landi
[1] L. Poliseno,et al. Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology , 2024, 3 Biotech.
[2] M. Taheri,et al. A review on the role of NDRG1 in different cancers , 2023, Molecular Biology Reports.
[3] Gary D Bader,et al. The reactome pathway knowledgebase 2022 , 2021, Nucleic Acids Res..
[4] E. A. Phelps,et al. Physical tuning of galectin-3 signaling , 2021, Proceedings of the National Academy of Sciences.
[5] L. Poliseno,et al. Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system. , 2020, Thyroid : official journal of the American Thyroid Association.
[6] Gautier Koscielny,et al. Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics , 2020, Nucleic Acids Res..
[7] Zhaoxia Wang,et al. Heterogeneous nuclear ribonucleoprotein (hnRNPL) in cancer. , 2020, Clinica chimica acta; international journal of clinical chemistry.
[8] L. Pieroni,et al. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome , 2020, Cancer Genomics & Proteomics.
[9] Jie-rong Huang,et al. Liquid-liquid phase separation and extracellular multivalent interactions in the tale of galectin-3 , 2020, Nature Communications.
[10] R. Maddala,et al. Calponin-3 deficiency augments contractile activity, plasticity, fibrogenic response and Yap/Taz transcriptional activation in lens epithelial cells and explants , 2020, Scientific Reports.
[11] S. Wiseman,et al. Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer , 2019, Expert review of anticancer therapy.
[12] W. Liang,et al. Galectin-3 may serve as a marker for poor prognosis in colorectal cancer: A meta-analysis. , 2019, Pathology, research and practice.
[13] Alka A. Potdar,et al. hnRNP L-mediated RNA switches function as a hypoxia-induced translational regulon. , 2019, Biochemical and biophysical research communications.
[14] Stephen Burgess,et al. PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations , 2019, Bioinform..
[15] P. Donnelly,et al. The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.
[16] A. Urbani,et al. A Proteomic Approach to Uncover Neuroprotective Mechanisms of Oleocanthal against Oxidative Stress , 2018, International journal of molecular sciences.
[17] V. Hogan,et al. Galectin-3 and cancer stemness , 2018, Glycobiology.
[18] L. Lavra,et al. Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z , 2018, International journal of molecular sciences.
[19] Jun Yan,et al. Galectin-3 rs4652 A>C polymorphism is associated with the risk of gastric carcinoma and P-glycoprotein expression level. , 2017, Oncology letters.
[20] Yu-Hao Lin,et al. The intrinsically disordered N-terminal domain of galectin-3 dynamically mediates multisite self-association of the protein through fuzzy interactions , 2017, The Journal of Biological Chemistry.
[21] Ming Li,et al. Correlations of Galectin-3 Gene Polymorphisms with Risk and Prognosis of Cervical Cancer in Chinese Populations: A Case-Control Study , 2017, Oncology Research and Treatment.
[22] Kyong-Tai Kim,et al. Heterogeneous nuclear ribonucleoprotein (hnRNP) L promotes DNA damage-induced cell apoptosis by enhancing the translation of p53 , 2017, Oncotarget.
[23] E. Leteurtre,et al. Galectin-3 is a non-classic RNA binding protein that stabilizes the mucin MUC4 mRNA in the cytoplasm of cancer cells , 2017, Scientific Reports.
[24] J. Jin,et al. Calponin isoforms CNN1, CNN2 and CNN3: Regulators for actin cytoskeleton functions in smooth muscle and non-muscle cells. , 2016, Gene.
[25] E. Sağlam,et al. LGALS3 and AXIN1 gene variants playing role in the Wnt/β-catenin signaling pathway are associated with mucinous component and tumor size in colorectal cancer , 2016, Bosnian journal of basic medical sciences.
[26] M. Bugliani,et al. Glucagon-like peptide 1 protects INS-1E mitochondria against palmitate-mediated beta-cell dysfunction: a proteomic study. , 2015, Molecular bioSystems.
[27] M. Sun,et al. Galectin-3 in cancer. , 2014, Clinica chimica acta; international journal of clinical chemistry.
[28] Andreas Krämer,et al. Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..
[29] F. Ciregia,et al. A multidisciplinary approach to study a couple of monozygotic twins discordant for the chronic fatigue syndrome: a focus on potential salivary biomarkers , 2013, Journal of Translational Medicine.
[30] Y. Wada,et al. Rock-dependent calponin 3 phosphorylation regulates myoblast fusion. , 2013, Experimental cell research.
[31] H. Westra,et al. A Genome-Wide Association Study of Circulating Galectin-3 , 2012, PloS one.
[32] Huamin Wang,et al. Overexpressed Galectin-3 in Pancreatic Cancer Induces Cell Proliferation and Invasion by Binding Ras and Activating Ras Signaling , 2012, PloS one.
[33] R. Bresalier,et al. A galectin‐3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells , 2011, Cancer.
[34] B. Caillou,et al. Wnt/β-Catenin Signaling Pathway Is a Direct Enhancer of Thyroid Transcription Factor-1 in Human Papillary Thyroid Carcinoma Cells , 2011, PloS one.
[35] V. Hogan,et al. Cleavage of galectin‐3 by matrix metalloproteases induces angiogenesis in breast cancer , 2010, International journal of cancer.
[36] J. Köhrle,et al. Proteomic approach reveals novel targets for retinoic acid-mediated therapy of thyroid carcinoma , 2010, Molecular and Cellular Endocrinology.
[37] Y. Kloog,et al. Galectin-3 Promotes Chronic Activation of K-Ras and Differentiation Block in Malignant Thyroid Carcinomas , 2010, Molecular Cancer Therapeutics.
[38] F. Couch,et al. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. , 2008, Cancer research.
[39] A. Pinchera,et al. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. , 2008, Journal of proteome research.
[40] B. Haugen,et al. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. , 2008, Cancer research.
[41] V. Hogan,et al. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. , 2007, Cancer research.
[42] Mirna Flögel,et al. Galectin-3: an open-ended story. , 2006, Biochimica et biophysica acta.
[43] V. Castronovo,et al. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3 , 2004, Oncogene.
[44] Y. Kloog,et al. Galectin-3 Augments K-Ras Activation and Triggers a Ras Signal That Attenuates ERK but Not Phosphoinositide 3-Kinase Activity* , 2004, Journal of Biological Chemistry.
[45] Yoshifumi Yamamoto,et al. Malignant transformation of thyroid follicular cells by galectin-3. , 2003, Cancer letters.
[46] A. Scaloni,et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. , 2003, Biochemical and biophysical research communications.
[47] L. Liotta,et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. , 1994, Biochemistry.
[48] M. Mattéi,et al. Thyroid nuclear factor 1 (TTF‐1) contains a homeodomain and displays a novel DNA binding specificity. , 1990, The EMBO journal.
[49] T. Dörk,et al. Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. , 2013, Urologic oncology.